0.50 / AMA PRA Category 1 CreditsTM 0.50 / AAPA Category 1 CME Credits 0.50 / CE for Nurse Practitioners (0.25 pharmacology credit)
This educational initiative is provided by CME Outfitters.
Supported by an educational grant from Allergan.
Schizophrenia is a chronic and debilitating disease, and pharmacotherapy for it has focused on the management of positive symptoms using atypical antipsychotics, leading to negative symptoms that contributed more to impaired quality of life being left untreated or underrated. Due to the persistent and chronic nature of negative symptoms, the need for effective therapy with a novel mechanism of action (MOA) is paramount.
This CME Outfitters Snack features expert faculty examining the impact on negative symptoms in remission and recovery, evaluating clinical trial updates on novel therapies with unique MOAs, and integrating pharmacologic knowledge of D3 receptor function as it pertains to treatment selection for the negative symptoms of schizophrenia.
Psychiatrists, primary care physicians, physician assistants, and nurse practitioners who treat patients with schizophrenia.
At the end of this CME/CE activity, participants should be able to:
Examine the clinical implications of negative symptoms of schizophrenia on recovery and restoration of function.
Evaluate clinical trial updates on novel therapies with unique mechanisms of action (MOAs) that address the negative symptoms of schizophrenia.
Integrate pharmacologic knowledge of D3 receptor function into individualized treatment selection for the negative symptoms of schizophrenia.
Conflict Of Interest Disclosure Policy
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
John Lauriello, MD (Moderator) Robert J. Douglas MD and Betty Douglas Distinguished Professor in Psychiatry Department of Psychiatry University of Missouri Medical Director University of Missouri Psychiatric Center Columbia, MO
Dr. Lauriello reports that he receives grants from Alkermes - Event Monitoring Board - Grant to the University of Missouri, Feb. 2017. He receives research support from Clinical research site - Florida Atlantic University Grant funded by Otsuka America Pharmaceutical, Inc. He is on the Alkermes Advisory Board (Nov. 2017). He receives other financial or material support from Alkermes - Co-author American Society of Psychopharmacology Poster.
Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra Northwell School of Medicine Hempstead, NY Investigator, Center for Psychiatric Neuroscience Feinstein Institute for Medical Research Manhasset, NY Medical Director, Recognition and Prevention (RAP) Program The Zucker Hillside Hospital, Department of Psychiatry Glen Oaks, NY
Dr. Correll reports that he receives grants and research support from Janssen Pharmaceutical, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Alkermes; Allergan; Angelini Pharma Inc.; Boehringer-Ingelheim; Gedeon Richter; Gerson Lehrman Group, Inc.; Indivior; IntraCellular Therapies; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; LB Pharmaceuticals; Lundbeck; MedAvante-ProPhase, Inc.; Neurocrine Biosciences, Inc.; Novel Pharmaceuticals, Inc.; Pfizer Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon Pharma Co., Ltd.; Sunovian Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceutical Industries Ltd. He is a stock shareholder (directly purchased) of Janssen Pharmaceutical, Inc.; and Otsuka America Pharmaceutical, Inc. He provides expert testimony for Bristol-Myers Squibb Company. He is a Data Safety Monitoring Board Member/Chair for Boehringer-Ingelheim; Lundbeck; Rovi; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceutical Industries Ltd.
Accredited Provider Disclosure
The CME Outfitters, LLC staff has nothing to disclose.
Planners' and Managers' Disclosures
Tony Graham, MD, (peer reviewer) has no disclosures to report. Mae Ochoa (peer reviewer) has no disclosures to report. Kashemi D. Rorie, PhD, (planning committee) has no disclosures to report. Jan Perez (planning committee) has no disclosures to report. Sharon Tordoff (planning committee) has no disclosures to report.
AMA PRA Category 1 Credit(s)TM
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Category I CME credit
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria.
This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid for one year from 05/24/19. PAs should only claim credit commensurate with the extent of their participation.
CE for Nurse Practitioners
This activity was planned in accordance with AANP Accreditation Standards and Policies.
This activity is approved for 0.50 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19043697.
MIPS Improvement Activity
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Disclosure of Unlabeled Use
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.
Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in this CME/CE activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.
To obtain a certificate, participants must receive a score of 75% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact CME Outfitters at 877-263-7767.